Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
BUDESONIDE FORMOTEROL FUMATRATE DIHYDRATE
AstraZeneca UK Limited
100/6 Microgram
Powder for Inhalation
2011-01-07
License Summary of Product Characteristics 1 NAME OF THE MEDICINAL PRODUCT Budfor 100micrograms/6micrograms/Inhalation, Inhalation powder 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each delivered dose (the dose that leaves the mouthpiece) contains: budesonide 80 micrograms/inhalation and formoterol fumarate dihydrate 4.5 micrograms/inhalation. Each metered dose contains: budesonide 100 micrograms/inhalation and formoterol fumarate dihydrate 6 micrograms/inhalation. Excipient: Lactose monohydrate 810 micrograms per dose. For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Inhalation powder White powder 4 CLINICAL PARTICULARS 4.1 Therapeutic Indications Budfor is indicated in the regular treatment of asthma where use of a combination (inhaled corticosteroid and long -acting 2 adrenoceptor agonist) is appropriate: - patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short -acting 2 adrenoceptor agonists. or - patients already adequately controlled on both inhaled corticosteroids and long -acting 2 adrenoceptor agonists. Note: Budfor (100 micrograms/6 micrograms/inhalation) is not appropriate in patients with severe asthma. 4.2 Posology and method of administration Route of administration: For inhalation use Budfor is not intended for the initial management of asthma. The dosage of the components of Read the complete document